+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Therapeutics Market by Therapeutic Mechanism (Chemotherapy, Hormone Therapy, Immunotherapy), Therapy Line (First Line, Second Line, Third Line And Beyond), Formulation, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Prostate Cancer Therapeutics Market by Therapeutic Mechanism (Chemotherapy, Hormone Therapy, Immunotherapy), Therapy Line (First Line, Second Line, Third Line And Beyond), Formulation, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Prostate Cancer Therapeutics Market by Therapeutic Mechanism (Chemotherapy, Hormone Therapy, Immunotherapy), Therapy Line (First Line, Second Line, Third Line And Beyond), Formulation, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896567
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The prostate cancer therapeutics market is moving through a period of accelerated advancement, driven by emerging therapies, precision medicine, and adaptive strategies to meet evolving patient needs and industry challenges.

Market Snapshot: Prostate Cancer Therapeutics Market

The prostate cancer therapeutics market expanded from USD 10.62 billion in 2024 to USD 11.32 billion in 2025. With a forecast CAGR of 6.34%, the sector is projected to reach USD 15.37 billion by 2030. This growth reflects increased adoption of next-generation therapies, integration of precision medicine, and a shifting regulatory environment favoring innovative treatment approaches.

Scope & Segmentation

  • Therapeutic Mechanism: Chemotherapy, including platinum compounds and taxanes; hormone therapies such as antiandrogens, CYP17 inhibitors, GnRH agonists, and GnRH antagonists; immunotherapies including cancer vaccines, cell therapy, and checkpoint inhibitors; radiopharmaceuticals with alpha and beta emitters; targeted therapies including monoclonal antibodies, Parp inhibitors, and tyrosine kinase inhibitors.
  • Therapy Line: Encompasses first-line, second-line, and third-line therapies or beyond, enabling treatment optimization at every disease stage.
  • Formulation: Both injectables and oral therapies are included, supporting flexibility from high-complexity clinical delivery to at-home regimens.
  • Distribution Channel: Hospital pharmacies, online platforms, and retail outlets are crucial routes, catering to diverse provider and patient preferences.
  • End User: Cancer centers, homecare providers, hospitals, and specialty clinics represent the primary users managing advanced and routine care.
  • Regional Coverage: Americas (including specific states and countries across North and South America), Europe, Middle East and Africa (with focus on both established and emerging healthcare systems), and Asia-Pacific (emphasizing markets such as China, India, Japan, and Southeast Asia).
  • Technology Adoption: The market leverages AI integration in diagnostics, next-generation sequencing, digital health platforms, and advancements in molecular imaging for enhanced clinical outcomes.

Key Takeaways

  • Treatment innovation is accelerating as stakeholders increasingly rely on real-world data, AI-enabled decision support, and adaptive trial designs to rapidly validate new protocols.
  • Immuno-oncology and radiopharmaceuticals are establishing new clinical benchmarks for efficacy and safety, reflected in expanding late-stage development pipelines and real-world adoption trends.
  • Segment-level strategy is essential; injectable forms remain standard in clinical settings, but oral options are driving patient convenience and adherence, influencing long-term outcomes.
  • Multinational partnerships and cross-sector alliances ensure robust commercialization and technology transfer, addressing barriers to access in both established and emerging regions.
  • Focus on health economic modeling and value-based contracting is intensifying, driving affordability and supporting the transition to outcome-centric reimbursement structures.

Tariff Impact on Access and Affordability

Recent U.S. tariff adjustments have introduced new cost pressures throughout the prostate cancer therapeutics supply chain. Manufacturers and distributors are pursuing alternative sourcing, while payers and providers are implementing risk-sharing agreements and investing in advanced trade management infrastructures to offset volatility. Stakeholders aligning early with trade and regulatory shifts are better placed to sustain patient access and manage cost risk.

Methodology & Data Sources

Insights in this report are based on rigorous triangulation, incorporating peer-reviewed literature, regulatory documents, proprietary databases, and interviews with senior oncology, regulatory, and commercial leaders. Multi-source analysis and expert validation underpin all data points, ensuring accuracy and objectivity.

Why This Report Matters

  • Delivers actionable intelligence for strategic decision-making, guiding investment, portfolio optimization, and commercial planning in prostate cancer therapeutics.
  • Equips executives to anticipate evolving technology trends, segment performance differentials, and emerging regulatory or tariff challenges to maintain competitive advantage.
  • Supports stakeholders aiming to align clinical innovation with payer requirements and regional market dynamics for sustainable long-term growth.

Conclusion

This report provides a clear, data-driven assessment of the prostate cancer therapeutics landscape, highlighting strategic levers for stakeholders. Informed decisions based on current trends and credible insights can drive future market success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of PARP inhibitors for metastatic castration-resistant prostate cancer in patients with BRCA mutations
5.2. Accelerating integration of PSMA-targeted radioligand therapy into second-line treatment protocols for advanced prostate cancer
5.3. Expansion of next-generation androgen receptor degraders showing promising outcomes in early hormone-sensitive prostate cancer trials
5.4. Integration of liquid biopsy-based genomic profiling to personalize treatment decisions in prostate cancer care pathways
5.5. Development of bispecific antibody therapies targeting PSMA and CD3 to enhance T-cell mediated prostate tumor eradication
5.6. Emergence of combination strategies pairing novel immunotherapy agents with existing hormonal therapies in prostate cancer
5.7. Advances in PSMA PET radiopharmaceuticals enabling earlier detection and real-time monitoring of prostate cancer progression
5.8. Growing utilization of artificial intelligence predictive analytics to optimize patient stratification and therapeutic selection in prostate cancer
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Prostate Cancer Therapeutics Market, by Therapeutic Mechanism
8.1. Introduction
8.2. Chemotherapy
8.2.1. Platinum Compounds
8.2.2. Taxanes
8.3. Hormone Therapy
8.3.1. Antiandrogens
8.3.2. CYP17 Inhibitors
8.3.3. GnRH Agonists
8.3.4. GnRH Antagonists
8.4. Immunotherapy
8.4.1. Cancer Vaccines
8.4.2. Cell Therapy
8.4.3. Checkpoint Inhibitors
8.5. Radiopharmaceuticals
8.5.1. Alpha Emitters
8.5.2. Beta Emitters
8.6. Targeted Therapy
8.6.1. Monoclonal Antibodies
8.6.2. Parp Inhibitors
8.6.3. Tyrosine Kinase Inhibitors
9. Prostate Cancer Therapeutics Market, by Therapy Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line And Beyond
10. Prostate Cancer Therapeutics Market, by Formulation
10.1. Introduction
10.2. Injectable
10.3. Oral
11. Prostate Cancer Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Prostate Cancer Therapeutics Market, by End User
12.1. Introduction
12.2. Cancer Centers
12.3. Homecare Providers
12.4. Hospitals
12.5. Specialty Clinics
13. Americas Prostate Cancer Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Prostate Cancer Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Prostate Cancer Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Astellas Pharma Inc.
16.3.2. Pfizer Inc.
16.3.3. Johnson & Johnson
16.3.4. F. Hoffmann-La Roche AG
16.3.5. Novartis AG
16.3.6. Bayer AG
16.3.7. AstraZeneca PLC
16.3.8. Sanofi S.A.
16.3.9. Bristol-Myers Squibb Company
16.3.10. Merck & Co., Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PROSTATE CANCER THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PROSTATE CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PROSTATE CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. PROSTATE CANCER THERAPEUTICS MARKET: RESEARCHAI
FIGURE 26. PROSTATE CANCER THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 27. PROSTATE CANCER THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 28. PROSTATE CANCER THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PROSTATE CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 135. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 136. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 137. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 138. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 139. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 140. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 141. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 142. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 143. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 144. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 145. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 146. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 147. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 148. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 149. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 150. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 151. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 156. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 157. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 158. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 159. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 160. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 161. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 162. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 163. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 166. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 167. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 170. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 171. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 258. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 259. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 260. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 261. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 262. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 263. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 264. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 265. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 266. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 268. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 269. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 270. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 271. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 272. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 273. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 278. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 279. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 280. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 281. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 282. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 283. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 284. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 285. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 286. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 287. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 288. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 289. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 290. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 291. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 292. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 293. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 3

Samples

Loading
LOADING...

Companies Mentioned

  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Bayer AG
  • AstraZeneca PLC
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.32 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.37 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Prostate Cancer Therapeutics - Global Strategic Business Report - Product Image

Prostate Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 212 Pages
  • Global
From
Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Prostate Health Market by Product Type (Diagnostic Kits, Drugs, Imaging Systems), Indication (Benign Prostatic Hyperplasia, Prostate Cancer, Prostatitis), End User, Distribution Channel, Technology Type - Global Forecast 2025-2030 - Product Image

Prostate Health Market by Product Type (Diagnostic Kits, Drugs, Imaging Systems), Indication (Benign Prostatic Hyperplasia, Prostate Cancer, Prostatitis), End User, Distribution Channel, Technology Type - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Global Market Report 2025 - Product Image

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Prostate Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2031F - Product Image

Prostate Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2031F

  • Report
  • 188 Pages
  • Global
From

About the Prostate Cancer Drugs Market

The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy. The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.